United States Neuromodulation Devices Market to Reach $42.78 Billion by 2033, Driven by Minimally Invasive Therapies & Rising Neurological Disorder Cases.

Leander, Texas and Tokyo, Japan - Dec.04.2025
As per DataM Intelligence research report, "The Global Neuromodulation Devices Market was valued at US$ 98.05 billion in 2023, reached US$ 104.26 billion in 2024, and is expected to reach US$ 190.14 billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033." Growing demand for minimally invasive therapies and rising cases of neurological disorders are boosting market expansion.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/neuromodulation-devices-market?praveen

United States: Recent Industry Developments
✅ In October 2025, Boston Scientific acquired the remaining equity of Nalu Medical for approximately US$ 533 million in cash. The acquisition brings Nalu's miniaturized, battery‐free peripheral nerve stimulation (PNS) implant system fully under Boston Scientific's control. It strengthens Boston Scientific's chronic pain neuromodulation portfolio and enables broader adoption of minimally invasive, patient-friendly PNS therapies in the U.S. market.

✅ In January 2025, NeuroBionics secured an oversubscribed seed funding round of US$ 5 million to advance its endovascular neuromodulation platform a minimally invasive, implantable system targeting neurological disorders. The investment accelerates R&D and supports bringing innovative neuromodulation options to patients who may avoid conventional invasive procedures.

Global: Recent Industry Developments
✅ In May 2025, Salvia BioElectronics raised US$ 60 million in a Series B financing round to support clinical development and global commercial launch of its migraine-targeted neuromodulation therapy, MySalvia Therapy. The therapy uses a minimally invasive implant to modulate nerves involved in chronic migraine. This funding underlines growing global investment in neuromodulation for neurological disorders and enables expansion to multiple regions including the U.S., Europe, and Australia.

✅ The Boston Scientific Nalu Medical acquisition (October 2025) also has global significance: Nalu's PNS technology is expected to be rolled out beyond the U.S., broadening access to minimally invasive neuromodulation solutions and strengthening the international chronic pain treatment landscape.

Key Developments
Salvia BioElectronics' Series B financing (May 2025) supports clinical trials, regulatory submissions, and international launch of its migraine neuromodulation implant. This development demonstrates growing confidence in non-pharmacological neuromodulation therapies.

NeuroBionics' seed funding (January 2025) accelerates development of endovascular neuromodulation, a novel, minimally invasive implantable approach targeting neurological disorders, expanding therapy options beyond traditional spinal or peripheral implants.

Mergers & Acquisitions
Boston Scientific's acquisition of Nalu Medical (October 2025) for US$ 533 million gives it full ownership of Nalu's PNS technology, integrating minimally invasive, wirelessly powered implants into its neuromodulation portfolio and expanding its global chronic pain offerings.

The acquisition positions Boston Scientific to compete more effectively in the U.S. and international neuromodulation markets, providing patients with less-invasive, next-generation peripheral nerve stimulation therapies.

Neuromodulation devices Market: Drivers
The neuromodulation devices market is expanding as demand grows for advanced therapies that offer targeted, non-pharmacological treatment for neurological and chronic pain conditions. These devices use electrical or magnetic stimulation to regulate neural activity, providing effective solutions for disorders such as Parkinson's disease, chronic pain, epilepsy, depression, and movement disorders. Rising prevalence of neurological conditions, increasing preference for minimally invasive treatments, and strong clinical success rates are driving market growth. Technological advancements in implantable systems, rechargeable pulse generators, and non-invasive stimulation devices are further improving patient comfort and therapeutic outcomes.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neuromodulation-devices-market?praveen

Neuromodulation devices Market: Major Players
Medtronic, Abbott, Boston Scientific Corporation, Integer Holdings Corporation, ElectroCore, NeuroPace, Inc., Nevro Corp, BrainsVVay, Neuronetics, Soterix Medical Inc.,

Segment Covered in the Neuromodulation devices Market:
By Product Type
Spinal cord stimulators lead with 45% share, driven by strong adoption in chronic pain therapy and minimally invasive procedures.
Deep brain stimulators hold 25%, widely used for Parkinson's disease and other movement disorders.
Vagus nerve stimulators account for 15%, supported by their effectiveness in epilepsy and treatment-resistant depression.
Other neuromodulation devices capture 15%, including sacral nerve, gastric, and peripheral nerve stimulators for specialized therapeutic needs.

By Indication
Pain management dominates with 50% share, fueled by the rising burden of chronic pain and a shift toward non-opioid treatment solutions.
Parkinson's disease and movement disorders hold 20%, supported by proven clinical outcomes from deep brain stimulation.
Epilepsy accounts for 15%, with increasing use of vagus nerve stimulation as adjunct therapy.
Other indications represent 15%, including depression, tremors, urinary incontinence, and gastrointestinal disorders.

By End-User
Hospitals lead with 55% share, driven by advanced neurology departments and high patient intake for surgical neuromodulation procedures.
Ambulatory surgical centers hold 25%, preferred for outpatient minimally invasive treatments.
Specialty clinics and neurological centers account for 15%, focusing on targeted pain and movement disorder management.
Other end-users represent 5%, including rehabilitation centers and research institutes.

Regional Analysis
North America - 38% Share
North America leads with 38%, driven by high prevalence of neurological disorders and strong adoption of advanced neuromodulation therapies supported by favorable reimbursement.

Europe - 28% Share
Europe holds 28%, supported by increasing use of spinal cord and deep brain stimulators, along with well-established healthcare systems in Germany, France, and the UK.

Asia Pacific - 26% Share
Asia Pacific accounts for 26%, fueled by rising neurological disease burden, expanding healthcare access, and growing adoption of implantable and non-invasive neuromodulation devices.

South America - 5% Share
South America holds 5%, driven by improving healthcare infrastructure and gradual uptake of advanced neurological treatment options in Brazil and Argentina.

Middle East & Africa - 3% Share
Middle East & Africa account for 3%, supported by increasing investment in modern healthcare technologies and growing awareness of neuromodulation therapies.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=neuromodulation-devices-market?praveen
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.